Voluntis
125 Cambridge Park Drive
Suite 304
Cambridge
Massachusetts
02140
United States
Tel: 617-401-2658
Website: http://www.voluntis.com/
Email: info@voluntis.com
About Voluntis
Pioneering therapeutic companion software, Voluntis innovates healthcare by embedding connectivity in therapeutics and medical intelligence in software. Dedicated to managing chronic conditions, Voluntis’ companion software aim to enable treatment personalization, to support team-care coordination and to improve real-world outcomes. Harnessing its proprietary technology, Voluntis has developed digital solutions for diabetes, cancer, anticoagulation treatments and haemophilia. Voluntis is headquartered in Paris, France, and has offices in Cambridge, MA.YEAR FOUNDED:
2001
LEADERSHIP:
Founder and CEO: Pierre Leurent
JOBS:
Please click here for Voluntis job opportunities.
FOLLOW VOLUNTIS:
Tweets by Voluntis
17 articles about Voluntis
-
Aptar Announces the Completion of the Acquisition of a Majority Stake in Voluntis
9/2/2021
AptarGroup, Inc. announced that following the signature of a share purchase agreement on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, it has completed the acquisition of a majority stake in Voluntis from the company's reference shareholders and certain members of the management.
-
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
3/3/2020
Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients.
-
Voluntis Announces New Pharma Collaboration in Oncology
12/18/2019
Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, announced today a collaboration with Novartis to evaluate the use of Voluntis’ digital therapeutic platform for Breast Cancer patients with the goal to empower patients with tools to more effectively manage symptoms and, thereby, improve patient experience and outcomes.
-
Voluntis Announces Market Authorization for Oleena™, First Digital Therapeutic in Oncology
7/31/2019
Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, today announced it has successfully completed a U.S. Food and Drug Administration (FDA) regulatory review of its Oleena™ software for oncology-related symptoms management and remote patient monitoring. Oleena™ is determined as Class II medical device falling under enforcement discretion per FDA Guidance.
-
AbbVie and Voluntis to Develop Companion Digital Therapeutics
12/19/2018
Voluntis (Paris:VTX) (Euronext Paris, Mnemo: VTX - ISIN: FR0004183960), a company specialized in digital therapeutics, announces today that it has entered into a collaboration with AbbVie, a research-based global biopharmaceutical company, to enhance patient care coordination in immunology with innovative digital therapeutic software.
-
Voluntis Announces End of Multi-Cancer Extension for Solution Developed with Roche Pharma France
10/24/2018
Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960) (Paris:VTX), a company specializing in digital therapeutics, announces Roche Pharma France's decision to end the agreement, announced in March 2018, to extend the ZEMY solution, initially developed in breast cancer, to all solid tumors.
-
Voluntis Releases Upgraded Version of Insulia to Improve User Experience, Including Spanish
8/16/2018
Voluntis announces the release of an upgraded version of Insulia that improves user experience and makes Insulia available in Spanish.
-
Voluntis: Results of the eCO Trial Published in the Journal of Clinical Oncology Informatics
7/16/2018
Voluntis announces that results for eCO, the digital therapeutic it developed for women with ovarian cancer in partnership with AstraZeneca and the National Cancer Institute, have been published in the Journal of Clinical Oncology (JCO®) Clinical Cancer Informatics.
-
Voluntis and Monarch Medical Technologies Announce Partnership to Provide Seamless Solution for Insulin Dosing Across the Continuum of Care
6/20/2018
Providers Can Bridge the Gap Between Inpatient and Outpatient Glycemic Management with Monarch's EndoTool® Glucose Management System and Voluntis' Insulia®
-
Voluntis announces its first contract with a US payer, WellDyneRx, for coverage of a digital therapeutic
5/14/2018
Insulia® to be added to WellDyneRx's WellManaged-Diabetes program
-
Voluntis Launches Insulia Savings Program, Making Insulia Available at $0 Copay
12/5/2017
Today, Voluntis launched the Insulia Savings Program, which gives Insulia users the opportunity to benefit from a $0 copay for up to twelve months.
-
Voluntis to Integrate Insulia With Onduo Virtual Diabetes Clinic
11/28/2017
The integrated solution will launch in pilot programs with US providers and payers in early 2018.
-
This now makes Insulia available for people using any brand of basal insulin including Lantus, Levemia, Toujeo, Tresiba and Basaglar.
-
Voluntis Receives FDA Clearance And CE Mark To Integrate Toujeo
7/18/2017
-
Ascensia Diabetes Care, Voluntis Ink Diabetes Technology Pact
6/9/2017
-
Voluntis Adds Scott Honken To Leadership Team To Strengthen Payer & Provider Focus
4/17/2017
-
Sanofi And Voluntis Announce A Global Alliance To Deliver Digital Insulin Titration Solutions For People With Type II Diabetes
3/14/2017